The authors strongly advocate for the WHO to lift its moratorium on pre-referral rectal artesunate for suspected childhood severe malaria, arguing that the observational data used to justify the ban is flawed.
⇒ The WHO recently recommended a moratorium on the implementation of pre-referral rectal artesunate for suspected childhood severe malaria.⇒ This was because of the lower referral completion rates and higher case fatality ratios in rectal artesunate recipients reported in a non-randomised, sequential observational study (CARAMAL) conducted in Nigeria, Uganda and the Democratic Republic of Congo.⇒ The observational study design, lack of a prespecified statistical analysis plan, strong temporal confounding, likely selection bias and the biological implausibility, all strongly challenge the interpretation of a causal relationship between rectal artesunate roll-out and increased mortality.⇒ Early mortality associated with delayed referral following rectal artesunate administration is more likely to have resulted from inadequate treatment of sepsis rather than malaria.⇒ Further delays in rectal artesunate roll-out resulting from inappropriate analysis and interpretation of the CARAMAL study will likely result in preventable childhood mortality.⇒ Stopping prereferral rectal artesunate is a grave error.The WHO should lift its moratorium on rectal artesunate deployment without delay
No takes yet. Share an insight, caveat, or question.
Watson et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: